BAE Systems, Inc. Names Tara Olivet Senior Vice President of Finance
FALLS CHURCH, Va.--(BUSINESS WIRE)--BAE Systems, Inc. has named Tara Olivet as its senior vice president of Finance, effective June 7.
Olivet will lead financial operations for the company's U.S.-based businesses, which generated 2024 sales of $16.85 billion and employs more than 40,000 employees across the United States, United Kingdom, and Sweden. She will also serve as a member of the BAE Systems, Inc. senior leadership team, reporting to President and CEO Tom Arseneault.
'During her 20-year tenure at BAE Systems, Tara has distinguished herself as a highly accomplished and widely respected executive,' said Arseneault. 'Her experience, leadership, and dedication to the company's mission will continue to be foundational to our future growth and success.'
Olivet joined BAE Systems in 2005 and has held numerous roles across the global enterprise, most recently serving as BAE Systems, Inc.'s deputy senior vice president of Finance, and prior to that, as vice president of Finance for the Platforms & Services sector. Before that, she spent six years with BAE Systems, Inc.'s headquarters team as the vice president of Internal Audit and Controller. Olivet also served as the finance and controls director for the U.K. Aircraft Carrier Alliance, which built and delivered the Queen Elizabeth Class Carriers to the Royal Navy, among other roles.
Olivet succeeds Dan Sallet, who will support special projects until his retirement in January.
'I want to thank Dan for the tremendous contributions he's made to our company throughout his more than 35-year career,' said Arseneault. 'His exceptional work has helped BAE Systems and its employees, customers, and shareholders to thrive.'
Olivet holds a Master of Business Administration from Georgetown University; a Bachelor of Business Administration in finance and marketing from Ithaca College; and a Certificate in Accounting from the University of California, Berkeley. She is also a Certified Public Accountant (CPA).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
35 minutes ago
- Wall Street Journal
Bank of New York Mellon Approached Northern Trust to Discuss Potential Merger
Bank of New York Mellon BK 0.02%increase; green up pointing triangle approached Northern Trust last week to express interest in merging with its smaller rival, people familiar with the matter said, in what would be a monster deal for the financial-services industry. The chief executives of BNY and Northern Trust had at least one conversation, the people said, though the firms didn't discuss a specific offer.
Business Upturn
an hour ago
- Business Upturn
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
an hour ago
- Business Upturn
FTRE FRAUD ALERT: Fortrea Holdings Inc. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by August 1 Legal Deadline (NASDAQ:FTRE)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting Investors have until August 1, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Fortrea securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Deslande v. Fortrea Holdings Inc., et al. , No. 1:25-cv-04630. Why was Fortrea Sued for Securities Fraud? Fortrea is a global contract research organization that provides biopharmaceutical product and medical device development solutions. In June 2023, Fortrea was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. ('Labcorp'). In connection with the spin-off, Fortrea entered into several transition services agreements (the 'TSAs'), pursuant to which it agreed to pay Labcorp for certain transitional services over a set period. As alleged, Fortrea discussed the significant cost savings and margin improvements that would result from exiting the TSAs. In truth, Fortrea overstated the cost savings and margin improvement it would achieve by exiting the TSAs, as well as the amount of revenue it would generate from pre-spin projects. The Stock Declines as the Truth is Revealed On September 25, 2024, investment bank Jefferies published a report stating that the cost savings Fortrea would achieve from exiting the TSAs were '[n]ot as [m]aterial as [o]ne [m]ight [t]hink.' On this news, the price of Fortrea stock declined $2.73 per share, or over 12%, from a closing price of $22.21 per share on September 24, 2024, to $19.48 per share on September 25, 2024. Then, on March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing that the company's pre-spin projects 'have less revenue and less profitability than expected for 2025' and that 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' On this news, the price of Fortrea stock declined $3.47 per share, or over 25%, from a closing price of $13.85 per share on February 28, 2025, to $10.38 per share on March 3, 2025, the next trading day. Click here if you suffered losses: What Can You Do? If you invested in Fortrea you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
